View in EDS HTML Full Text PDF Full Text

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Saved in:
Bibliographic Details
Title: Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Authors: Peñalver, Francisco‐Javier1 (AUTHOR) fjpenalver@fhalcorcon.es, Márquez, José‐Antonio2 (AUTHOR), Durán, Soledad3 (AUTHOR), Giraldo, Pilar4 (AUTHOR), Martín, Alejandro5 (AUTHOR), Montalbán, Carlos6 (AUTHOR), Sancho, Juan‐Manuel7 (AUTHOR), Ramírez, María‐José8 (AUTHOR), Terol, María‐José9 (AUTHOR), Capote, Francisco‐Javier10 (AUTHOR), Gutiérrez, Antonio11 (AUTHOR), Sánchez, Blanca12 (AUTHOR), López, Andrés13 (AUTHOR), Salar, Antonio12 (AUTHOR), Rodríguez‐Caravaca, Gil14 (AUTHOR), Canales, Miguel15 (AUTHOR), Caballero, María‐Dolores5 (AUTHOR)
Source: Cancer Medicine. Nov2019, Vol. 8 Issue 16, p6955-6966. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.2555